Anthropic starts developing its own medicines

Anthropic is now creating its own experimental treatments, shifting from creating AI tools to conducting hands-on medical research.

A report from October 27, 2026, revealed the firm has launched its own drug development initiatives, prioritizing childhood muscular dystrophy cases, alongside collaborations with six biotech firms.

This internal push builds on Mithril Medicine, a solo venture developing therapies for two rare muscle-wasting diseases, which Anthropic has now acquired.

The company’s founder, Cody Tranbarger, relied on Anthropic’s Claude system to manage agreements, logistics, and experiments across 11 labs, advancing a potential therapy from concept to mouse testing in under 18 months.

Tranbarger has joined Anthropic full-time and intends to launch additional projects, with the company projecting a candidate could enter human testing by late 2028—if preclinical results remain strong.

Early Results and Challenges

The science is still at a very early stage. Anthropic is working on a treatment for a rare muscle-wasting condition that affects children from birth, and the treatment is a specially designed antibody, a type of protein that can latch onto particular targets in the body.

So far it has only been tried on mice, and in that small test, mice given one version of the treatment were about twice as strong, in both muscle force and grip, as mice given a dummy solution with no medicine in it.

While the findings are optimistic, they carry significant caveats: the study hasn’t been reviewed by external experts and was a preliminary exploration rather than a rigorous, controlled study.

The study was an early investigation, not a tightly controlled experiment. The researchers did not always follow strict laboratory standards, randomly assign mice to groups, or keep testers unaware of which mice received the treatment.

Partnerships and Future Directions

Cancer treatment is mentioned indirectly—Anthropic suggests its broader work could lead to oncology drugs, but current examples stem from partnerships rather than its own labs.

Generate Biomedicines used Claude Code to design a CAR-T component about 70% shorter than the standard version, which in lab tests let immune cells make roughly 10 times as many cancer-spotting receptors, a step towards treating solid tumors.

BigHat Biosciences tested about 1,010 variants of a cancer-targeting antibody fragment in around 10 weeks, with the best versions binding more than 10 times more tightly.

Bristol Myers Squibb is using Claude to assess clinical trial plans, with Michael Pourdehnad saying Claude produced an initial analysis from a single prompt “which would otherwise take days to complete,” though none of these is an Anthropic-owned cancer drug candidate.

Efficiency and Time Savings

Some of the biggest time savings come from paperwork. At Enveda, reviewing 1,061 pages of manufacturing documents took less than three hours, down from more than 25 hours.

Claude also drafted a regulatory document in four hours, a task that would have taken about three months. These examples suggest AI could save time not just in drug discovery, but also in the paperwork and processes needed to bring a drug to market.

Anthropic says the programs show where its models fall short and that the plan is to scale the work up substantially. The fair reading is that it has moved into early-stage biomedical research, with rare pediatric muscular dystrophy as its clearest in-house focus and no drug yet in human trials.